RSI Overbought Stocks
BIO is RSI overbought, meaning strong buying pressure may lead to a short-term consolidation or pullback.
BIO-RAD LABORATORIES-A (BIO) Stock Price & Overview
NYSE:BIO • US0905722072
Current stock price
305.67 USD
+2.33 (+0.77%)
At close:
305.67 USD
0 (0%)
After Hours:
The current stock price of BIO is 305.67 USD. Today BIO is up by 0.77%. In the past month the price increased by 15.35%. In the past year, price increased by 25.98%.
BIO Key Statistics
52-Week Range211.43 - 343.12
Current BIO stock price positioned within its 52-week range.
1-Month Range260.585 - 312.85
Current BIO stock price positioned within its 1-month range.
- Market Cap
- 8.25B
- P/E
- 30.81
- Fwd P/E
- 29.62
- EPS (TTM)
- 9.92
- Dividend Yield
- N/A
BIO Stock Performance
Today
+0.77%
1 Week
+4.60%
1 Month
+15.35%
3 Months
+3.07%
Longer-term
6 Months -10.03%
1 Year +25.98%
2 Years +13.32%
3 Years -32.19%
5 Years -51.49%
10 Years +115.49%
BIO Stock Chart
BIO Stock Screens
BIO currently appears in the following ChartMill screener lists.
BIO Technical Analysis
ChartMill assigns a technical rating of 6 / 10 to BIO. When comparing the yearly performance of all stocks, BIO turns out to be only a medium performer in the overall market: it outperformed 67.42% of all stocks.
Chartmill TA Rating
Chartmill Setup Rating
BIO Fundamental Analysis
ChartMill assigns a fundamental rating of 5 / 10 to BIO. BIO is in great health and has no worries on liquidiy or solvency at all, but the profibility rating is only average.
Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend
BIO Earnings
On February 12, 2026 BIO reported an EPS of 2.51 and a revenue of 693.20M. The company missed EPS expectations (-7.97% surprise) and missed revenue expectations (-0.35% surprise).
Next Earnings DateApr 30, 2026
Last Earnings DateFeb 12, 2026
PeriodQ4 / 2025
EPS Reported$2.51
Revenue Reported693.2M
EPS Surprise -7.97%
Revenue Surprise -0.35%
BIO Forecast & Estimates
10 analysts have analysed BIO and the average price target is 326.4 USD. This implies a price increase of 6.78% is expected in the next year compared to the current price of 305.67.
For the next year, analysts expect an EPS growth of 4.02% and a revenue growth 2.04% for BIO
Analysts
Analysts76
Price Target326.4 (6.78%)
EPS Next Y4.02%
Revenue Next Year2.04%
BIO Groups
Sector & Classification
BIO Financial Highlights
Over the last trailing twelve months BIO reported a non-GAAP Earnings per Share(EPS) of 9.92. The EPS decreased by -3.78% compared to the year before.
Income Statements
Revenue(TTM)2.58B
Net Income(TTM)759.90M
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 29.42% | ||
| ROA | 7.18% | ||
| ROE | 10.2% | ||
| Debt/Equity | 0.16 |
Chartmill High Growth Momentum
EPS Q2Q%-13.45%
Sales Q2Q%3.85%
EPS 1Y (TTM)-3.78%
Revenue 1Y (TTM)0.65%
BIO Ownership
Ownership
Inst Owners90.49%
Shares26.99M
Float18.35M
Ins Owners8.11%
Short Float %6.62%
Short Ratio3.96
BIO Competitors/Peers
The largest stocks on the US markets in the "Life Sciences Tools & Services" sub-industry
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| TMO | THERMO FISHER SCIENTIFIC INC | 21.14 | 194.941B | ||
| DHR | DANAHER CORP | 21.13 | 137.676B | ||
| BRKRP | BRUKER CORP - BRKR 6 3/8 09/01/28 | 147.78 | 48.612B | ||
| A | AGILENT TECHNOLOGIES INC | 18.17 | 34.503B | ||
| WAT | WATERS CORP | 23.05 | 32.91B | ||
| IQV | IQVIA HOLDINGS INC | 13.7 | 29.493B | ||
| MTD | METTLER-TOLEDO INTERNATIONAL | 28.2 | 26.817B | ||
| ILMN | ILLUMINA INC | 25.22 | 20.049B | ||
| WST | WEST PHARMACEUTICAL SERVICES | 33.88 | 19.802B | ||
| MEDP | MEDPACE HOLDINGS INC | 29.49 | 14.706B | ||
| RVTY | REVVITY INC | 17.13 | 10.539B | ||
| TEM | TEMPUS AI INC-CL A | N/A | 9.894B | ||
| TECH | BIO-TECHNE CORP | 26.86 | 9.335B |
Related stock screener links
View all stocks in the Life Sciences Tools & Services Industry | View all stocks in the Health Care Sector | View all stocks on the New York Stock Exchange Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About BIO
Company Profile
Bio-Rad Laboratories, Inc. engages in the development and production of specialty chemicals used in biochemical, pharmaceutical, and other life science research applications. The company is headquartered in Hercules, California and currently employs 7,450 full-time employees. The firm offers a range of products and systems used to separate complex chemical and biological materials and to identify, analyze and purify their components. The company operates through two segments: Life Science and Clinical Diagnostics. The Life Science segment develops, manufactures, and markets instruments, systems, reagents, and consumables used for biological research, biopharmaceutical production processes, food testing regimes, and science education. Its Clinical Diagnostics segment designs, manufactures, markets and supports test systems, informatics systems, test kits and specialized quality controls that serve clinical laboratories in the global diagnostics market. These products are sold to hospital laboratories, diagnostic reference laboratories, transfusion laboratories, and physician office laboratories.
Company Info
IPO: 1980-03-17
BIO-RAD LABORATORIES-A
1000 Alfred Nobel Dr
Hercules CALIFORNIA 94547 US
CEO: Norman Schwartz
Employees: 7450
Phone: 15107247000
BIO-RAD LABORATORIES-A / BIO FAQ
What does BIO do?
Bio-Rad Laboratories, Inc. engages in the development and production of specialty chemicals used in biochemical, pharmaceutical, and other life science research applications. The company is headquartered in Hercules, California and currently employs 7,450 full-time employees. The firm offers a range of products and systems used to separate complex chemical and biological materials and to identify, analyze and purify their components. The company operates through two segments: Life Science and Clinical Diagnostics. The Life Science segment develops, manufactures, and markets instruments, systems, reagents, and consumables used for biological research, biopharmaceutical production processes, food testing regimes, and science education. Its Clinical Diagnostics segment designs, manufactures, markets and supports test systems, informatics systems, test kits and specialized quality controls that serve clinical laboratories in the global diagnostics market. These products are sold to hospital laboratories, diagnostic reference laboratories, transfusion laboratories, and physician office laboratories.
Can you provide the latest stock price for BIO-RAD LABORATORIES-A?
The current stock price of BIO is 305.67 USD. The price increased by 0.77% in the last trading session.
Does BIO-RAD LABORATORIES-A pay dividends?
BIO does not pay a dividend.
What is the ChartMill technical and fundamental rating of BIO stock?
BIO has a ChartMill Technical rating of 6 out of 10 and a ChartMill Fundamental rating of 5 out of 10.
What do analysts say about BIO-RAD LABORATORIES-A (BIO) stock?
10 analysts have analysed BIO and the average price target is 326.4 USD. This implies a price increase of 6.78% is expected in the next year compared to the current price of 305.67.
What is the expected growth for BIO stock?
The Revenue of BIO-RAD LABORATORIES-A (BIO) is expected to grow by 2.04% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
What is the ownership structure of BIO-RAD LABORATORIES-A (BIO)?
You can find the ownership structure of BIO-RAD LABORATORIES-A (BIO) on the Ownership tab.